ClinicalTrials.gg
RecruitingNCT06290817Updated Mar 4, 2024

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

A Phase 2 interventional study of Orelabrutinib combined with R-CDOP regimen in Diffuse Large B-cell Lymphoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Mar 2023, registered Feb 2024).
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
4th of 11
62 · median 39
Started
2023
with 1 other
Phase 2
8 of 11
6 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by planned enrollment, is one of 2 that started in 2023, is one of 8 in phase 2, and was the 6th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a prospective, multicenter, single-arm clinical study on the treatment of newly diagnosed diffuse large B-cell lymphoma with high-risk of CNS relapse defined by CNS-IPI using Orelabrutinib in combination with R-CDOP regimen.

Read the detailed description

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of B-cell lymphoma, where the dual expression of Myc and BCL-2 genes in non-germinal center B-cell like (non-GCB) lymphomas is associated with a poor prognosis when treated with the standard R-CHOP regimen. Bruton's tyrosine kinase (BTK), a key kinase in the B-cell receptor (BCR) signaling pathway, is an important target for the treatment of B-cell lymphomas. Studies have shown that the first-generation BTK inhibitor Ibrutinib when combined with the R-CHOP regimen for previously untreated patients with dual-expressing, non-GCB lymphomas, can improve event-free survival rates. Orelabrutinib, as a new generation BTK inhibitor independently developed in China, possesses higher inhibitory activity against BTK kinase and can penetrate the blood-brain barrier, offering potential benefits for patients at high risk of central nervous system relapse. The novel anthracycline drug-Liposomal Doxorubicin, which has almost no cardiac toxicity, suggests that the combination of Orelabrutinib with the R-CDOP regimen could improve the adverse prognosis of DLBCL patients at high risk of central relapse. This is a prospective, multicenter, single-arm clinical study on the treatment of newly diagnosed diffuse large B-cell lymphoma with high-risk CNS-IPI using Orelabrutinib in combination with R-CDOP regimen. All participants were treated with the Orelabrutinib combined with R-CDOP regimen. The treatment cycles were set every 21 days for a total of 6-8 cycles. During the study treatment period, researchers conducted a tumor assessment (with a 1-week time window allowed) after the screening period and once again after the 4th, 6th, or 8th cycle of treatment to evaluate the antitumor efficacy of the investigational drug. After all treatment cycles were completed, follow-up visits were conducted every 3 months until the end of the 3-year period. The median duration of follow-up was 24 months.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old; score 0-3;
  2. confirmed diffuse large B-cell lymphoma, including DLBCL and transformed DLBCL;
  3. CNS-IPI≥4 points
  4. Previously untreated participants with CD20-positive DLBCL,;
  5. Heart, liver, and kidney function: creatinine \< 2 times the normal upper limit (); (alanine aminotransferase)/AST (Aspartate Aminotransferase) \< 2.5ULN; Total \< 2ULN; Cardiac (EF) ≥50%.
  6. At least one .
  7. Have the sufficient understanding ability and voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  1. Patients with evidence of CNS involvement ;
  2. active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease as determined by the (NYHA) functional scale, or a history of myocardial infarction within 6 months before screening;
  3. (HIV) infection;
  4. Pregnant or lactating women;
  5. Other tumors that require treatment;
  6. Uncontrolled active infection;
  7. The copy number of active hepatitis after antiviral treatment can not be controlled within 2×103/ml.
  8. unable to understand and follow the research protocol or unable to sign the .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib combined with R-CDOP regimen

    Participants will receive 150 mg of oral orelabrutinib once daily with R-CDOP on day 1 of each cycle (21 days)

    Drug: Orelabrutinib combined with R-CDOP regimen

Interventions

  • DrugOrelabrutinib combined with R-CDOP regimen

    Drug page: OrelabrutinibStudies of OrelabrutinibOrelabrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants were treated with the orelabrutinib combined with R-CHOP regimen (O-RCDOP). The treatment plan involved orelabrutinib tablets at 150mg QD (once daily) from day 1 to day 21, Rituximab at 375mg/m2 on day 1; Cyclophosphamide at 750mg/m2 on day 1; Liposomal Doxorubicin at 30mg/m2 on day 0; Vincristine at 25mg/m2 on day 1 (maximum dose 40mg); and Prednisone at 100mg from day 1 to day 5. The treatment cycles were set every 21 days for a total of 6-8 cycles. Dose adjustments were made for elderly patients for Cyclophosphamide and Liposomal Doxorubicin based on age: 70-80% of the dose for those aged 70-80 years old, and 50-60% of the dose for those older than 80 years.

06

What researchers measure

Primary outcomes

  1. 2-year central nervous system relapse rate

    The proportion of patients with central nervous system recurrence within two years from enrollment accounted for all patients treated with drugs.

    Time frame: up to 2 years

Secondary outcomes

  1. Complete Response Rate

    The rate of patients who achieved complete response after treatment.

    Time frame: At the end of Cycle 3 and Cycle 6(each cycle is 21 days)

  2. Overall Response Rate (ORR)

    The rate of patients who achieved CR or PR after treatment.

    Time frame: At the end of Cycle 3 and Cycle 6(each cycle is 21 days)

  3. 2-year Overall survival (OS) rate

    2-year overall survival (OS) rate Accessed by the investigator

    Time frame: Up to 2 years

  4. 1-year Overall survival (OS) rate

    1-year overall survival (OS) rate Accessed by the investigator

    Time frame: Up to 1 year

  5. 2-year progression-free survival (PFS) rate

    Number of non-progression cases/all enrolled cases at 2 years

    Time frame: 2 years after enrollment of final patient

  6. 1-year progression-free survival (PFS) rate

    Number of non-progression cases/all enrolled cases at 1 year

    Time frame: 1 year after enrollment of final patient

  7. Occurrence of hematologic adverse events and non-hematologic adverse events according to CTCAE V4.03

    The safety of Orelabrutinib is measured by the occurrence of hematologic adverse events and non-hematologic adverse events according to CTCAE V4.03

    Time frame: Up to 3 years

Other outcomes

  1. Occurrence of adverse events and serious adverse events according to CTCAE V4.03

    The safety of Orelabrutinib measured by the occurrence of adverse events and serious adverse events according to CTCAE V4.03.

    Time frame: Up to 3 years

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2025, 24 months after the start.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 24 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 4, 2024
StartActual
Mar 30, 2023
Primary completionEst.
Mar 30, 2025
CompletionEst.
Mar 20, 2026
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06290817
Collaborators
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Huizhou Municipal Central Hospital, Ningbo Medical Center Lihuili Hospital, Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Mar 30, 2023
Primary completion
Mar 30, 2025 (estimated)
Completion
Mar 20, 2026 (estimated)
Last update
Mar 4, 2024

Study contacts

Xibin Xiao
Contact
xiaoxibinzju@zju.edu.cn
13858015535
Wenbin Qian
study director · 15.1 Second affiliated hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion